Voyager Therapeutics is trading at $2.35, down 5.06%, amid biotech sector pressure. - The provided sector context reports XBI down 2.04%, pointing to sector weakness rather than a confirmed company-specific catalyst. - No October 8 company announcement was found; Voyager’s latest listed release is dated September 1. - Broader risk-off sentiment amid geopolitical tensions, higher oil prices and elevated Treasury yields may add pressure, though available evidence does not establish a direct cause.